FC
UTHR icon

Farringdon Capital’s United Therapeutics UTHR Stock Holding History

Farringdon Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,638
Closed -$1.77M – 600
2025
Q4 		$1.77M Buy
3,638
+3,019
+488% +$1.41M 0.44% 62
2025
Q3 		$259K Buy
+619
New +$208K 0.07% 353
2025
Q1 		– Sell
-828
Closed -$292K – 611
2024
Q4 		$292K Buy
+828
New +$304K 0.12% 289

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Farringdon Capital's UTHR Position: Q1 2026 in Review

Farringdon Capital sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 3,638 shares — an estimated $1.77M sold.

Farringdon Capital first reported a position in UTHR in Q4 2024 and held it in 3 quarters. The position peaked at $1.77M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Farringdon Capital reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Farringdon Capital sold 3,638 United Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Farringdon Capital first reported a position in United Therapeutics in Q4 2024 and held it in 3 quarters.
  • Farringdon Capital's United Therapeutics position peaked at $1.77M in Q4 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.